← All trials
NCT06385522
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2024
- Primary completion
- Feb 28, 2027
- Completion date
- Feb 28, 2027
- First posted
- Apr 26, 2024
- Last posted
- Apr 26, 2024
- Enrollment
- 37
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Boston Immune Technologies and TherapeuticsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.